Cidara Therapeutics, Inc. announced that on April 21, 2024, in accordance with the terms of the Securities Purchase Agreement, each of Timothy R. Franson, M.D., and David Gollaher, Ph.D. tendered their resignations from the Board, contingent on and effective as of immediately prior to the closing of the Private Placement. The resignation of each of Drs. Franson and Gollaher is not a result of any disagreement with the Company on any matter relating to the Company?s operations, policies or practices.

Effective as of the closing of the Private Placement, the Board increased the number of directors to nine and upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed James Merson, Ph.D., Ryan Spencer, and Laura Tadvalkar, Ph.D., as directors of the Company. Dr. Merson will serve as a Class III director with an initial term expiring at the Company?s 2024 annual meeting of stockholders, Mr. Spencer will serve as a Class I director with an initial term expiring at the Company?s 2025 annual meeting of stockholders, and Dr. Tadvalkar will serve as a Class II director with an initial term expiring at the Company?s 2026 annual meeting of stockholders, in each case, until his or her successor is duly elected and qualified, or until his or her earlier death, resignation, or removal. Concurrent with his appointment to the Board, Dr. Merson was appointed as a member of the Nominating and Corporate Governance Committee of the Board.